Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis
Article 1993 en
Authors
CF
Charles J. Fisher
SO
Steven M. Opal
JD
Jean-François Dhainaut
Abstract
1 min read
The murine anti-TNF-alpha monoclonal antibody CB0006 has proven to be safe in this clinical trial and may prove to be useful in septic patients with increased circulating TNF concentrations. Further studies are needed to determine efficacy and the ultimate clinical utility of this immunotherapeutic agent in sepsis.
Jean-François Dhainaut, Jean Louis Vincent, Christian Richard, Philippe Lejeune, Claude Martin, Lisiane Fierobe, Sue Stephens, Ursula M. Ney, Mark Sopwith
Gordon R. Bernard, Bruno François, Jean-Paul Mira, Jean Louis Vincent, R. Phillip Dellinger, James A. Russell, Steven P. LaRosa, Pierre‐François Laterre, Mitchell M. Levy, Wayne M. Dankner, Nicola Schmitt, Justin P.O. Lindemann, Xavier Wittebole
Danay Saavedra, Ana Laura Añé-Kourí, Naivy Sánchez, Lázaro Manuel Filgueira, Julio L. Betancourt, Carlos Herrera, Leniel Manso, Elibet Chávez, Armando Caballero, C. Hidalgo, Geydi Lorenzo, Meylán Cepeda, Carmen Valenzuela, Mayra Ramos, Kalet León, Zaima Mazorra, Tania Crombet
Discussion(0)
No comments yet. Be the first to comment.